Malignant mast cell neoplasm Terminated Phase 2 Trials for Ibrutinib (DB09053)

Also known as: Malignant Mast Cell Tumors / Mast Cell Leukemia (MCL) / Leukemia, Mast Cell / Mast Cell Leukemia / Malignant-mast cell tumours / Mast-Cell Sarcoma

IndicationStatusPhase
DBCOND0007107 (Malignant mast cell neoplasm)Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02415608Ibrutinib in Treating Patients With Advanced Systemic MastocytosisTreatment